TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07227454: A Double-blind, Randomized, Psychoactive Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine 84 mg in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms o

Sponsor: Janssen Research & Development, LLC · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 258 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$10,230,248

Rescue Site Savings

+$6,741,592

Unlock Full NCT07227454 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07227454 Rescue Dossier →